skip to main content
Show Results with:

Next generation antibody drug conjugates (ADCs) and immunotoxins / Ulf Grawunder, Stefan Barth, editors.

Cham : Springer, 2017.

Online access

  • Title:
    Next generation antibody drug conjugates (ADCs) and immunotoxins / Ulf Grawunder, Stefan Barth, editors.
  • Contributor: Ulf Grawunder editor.;
    Stefan Barth editor.
  • Subjects: Medicine; Antibody-toxin conjugates; Immunotoxins; MEDICAL -- Pharmacology; Antibody-toxin conjugates; Medical -- Immunology; Medical -- Oncology; Immunology; Pharmacology; Oncology; Toxicology; Monoclonal antibodies; Oncology; Oncology  ; Electronic books;
    Dewey: 615.7/98
  • Rights: Terms governing use: Copyright.
    Access restrictions: NON_PRINT_LEGAL_DEPOSIT
  • Publication Details: Cham : Springer, 2017.
  • Language: English
  • Description: Contents: Preface; The Complexity of ADCs and ITs; Contents; Chapter 1: Chemical Assembly of Antibody-Drug Conjugates; 1.1 Introduction; 1.2 Conjugation via Natural Amino Acid Residues; 1.2.1 Random Conjugation at Native Cysteine Residues; 1.2.2 Site-Specific Conjugation at Engineered Cysteine Residues; 1.2.3 Stabilization of Maleimide Linkage; 1.2.4 Hydrophilic Spacers; 1.2.5 Cysteine-Bridged Conjugation; 1.2.6 Site-Specific Conjugation at Engineered Selenocysteine Residues; 1.2.7 Random Conjugation at Native Lysine Residues; Maytansinoid ADCs; Calicheamicin ADCs.
    Contents: 1.3 Conjugation via Unnatural Amino Acids1.3.1 Site-Specific Conjugation at Engineered p-Acetyl-Phe Residues; 1.3.2 Site-Specific Conjugation at Engineered p-Azidomethyl-Phe Residues; 1.3.3 Site-Specific Conjugation at Engineered Formylglycine Residues; 1.4 Conclusions; References; Chapter 2: Preclinical Evaluation of ADCs Delivering Highly Potent Pyrrolobenzodiazepine (PBD) Dimers; 2.1 Background to the PBDs; 2.2 Antibody PBD Conjugates (APCs); 2.2.1 C2-Linked APCs; 2.2.2 N10-Linked APCs; 2.3 Emerging Clinical Data; 2.4 Properties and Advantages of APCs; 2.5 Conclusions; References.
    Contents: Chapter 3: Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents3.1 Introduction; 3.2 Bis-Sulphone Reagents for Disulphide Bridging Conjugation; 3.3 Reagent; 3.4 ADC Characterisation; 3.4.1 ADC Stability; 3.5 In Vitro Potency; 3.6 In Vivo Efficacy; 3.7 Antibody Fragments; 3.8 Fab Drug Conjugates; 3.9 Imaging Applications; 3.10 Conclusion; References; Chapter 4: Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications; 4.1 Mechanism of Action of Calicheamicin as an ADC Payload.
    Contents: 4.2 Preclinical Activities of Inotuzumab Ozogamicin4.3 Preclinical and Clinical Experience with Gemtuzumab Ozogamicin; 4.4 Ephrin-A4 (EFNA4): A Novel Target for Calicheamicin Conjugates; 4.5 Antitumor Activity of the EFNA4-ADC Against CSCs in Triple Negative Breast Cancer (TNBC) and Ovarian Carcinomas (OVCA)PDX ... ; 4.6 Conclusions and Future Perspectives; References; Chapter 5: Enzyme-Based Strategies to Generate Site-Specifically Conjugated Antibody Drug Conjugates; 5.1 Introduction; 5.2 Enzymatic Conjugation Technologies Used for the Generation of Site-Specifically Conjugated ADCs.
    Contents: 5.2.1 Strategies Involving Bacterial Transglutaminase (BTG) Enzyme5.2.2 Use of Sortase Enzymes for Generating Homogeneous ADCs; 5.2.3 Formyl-glycine Converting Enzyme (FGE) Approach; 5.2.4 Split Inteins for Generating Site-Specifically Conjugated ADCs; 5.2.5 Glycan-Remodeling Approaches to Create Handles for Site-Specific Conjugation; 5.2.6 Other Enzymatic Approaches; 5.3 Conclusions; References; Chapter 6: Substance P-Saporin for the Treatment of Intractable Pain; 6.1 Introduction; 6.2 Animal and Human Tests of SP-SAP; 6.2.1 The Substance-P and Saporin Molecules.
  • Identifier: ISBN 9783319468778 (electronic bk.); ISBN 3319468774 (electronic bk.)
    10.1007/978-3-319-46877-8 doi; BNB GBB901657; System number: 019191436
  • Notes: Bibliography note: Includes bibliographical references and index.
  • Physical Description: 1 online resource.
  • Series: Milestones in drug therapy
  • Shelfmark(s): General Reference Collection DRT ELD.DS.374081
  • UIN: BLL01019191436

Searching Remote Databases, Please Wait